Underwater: Medicare Negotiated Prices For Part B Cancer Drugs Could Change Prescribing

Anticipation that reimbursement for significantly discounted Keytruda and Opdivo won’t keep them afloat will influence treatment decisions by oncology providers, officials predict.

Oncology Practices Worry Reimbursement Won't Cover Costs • Source: Shutterstock

Medicare price negotiation for Part B oncology drugs will have ramifications across Medicare and commercial insurance markets because of the way that reimbursement works for physician-administered drugs, experts predicted at the Association of Value-Based Cancer Care educational summit on 18 October.

Practices are already thinking about shifting prescribing to a non-negotiated therapeutic equivalents or referring patients to hospitals for treatment if...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Medicare

More from Government Payers